Published in Nat Rev Clin Oncol on February 09, 2010
Evolution of the cancer genome. Nat Rev Genet (2012) 3.24
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res (2011) 1.68
Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer (2014) 1.67
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer (2013) 1.60
Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res (2011) 1.43
Marine ω-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer Characterized by Tumor-Infiltrating T Cells. JAMA Oncol (2016) 1.41
Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn (2011) 1.27
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clin Cancer Res (2015) 1.27
The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One (2012) 1.26
Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res (2014) 1.18
DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene (2012) 1.15
Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol (2013) 1.14
Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov (2013) 1.10
Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. Cell (2016) 1.08
Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. Int J Clin Oncol (2012) 1.04
The detection and implication of genome instability in cancer. Cancer Metastasis Rev (2013) 1.01
A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency. J Pathol (2012) 1.00
Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep (2014) 1.00
Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol (2015) 0.99
Comprehensive genome- and transcriptome-wide analyses of mutations associated with microsatellite instability in Korean gastric cancers. Genome Res (2013) 0.97
Classification and characterization of microsatellite instability across 18 cancer types. Nat Med (2016) 0.97
Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn (2011) 0.97
Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol (2015) 0.96
Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer. Cancer Biomark (2013) 0.94
Cancerous stem cells: deviant stem cells with cancer-causing misbehavior. Stem Cell Res Ther (2010) 0.91
Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis. BMC Med Genomics (2013) 0.91
Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. Br J Cancer (2012) 0.90
Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist (2013) 0.89
High-level microsatellite instability in appendiceal carcinomas. Am J Surg Pathol (2013) 0.88
Era of universal testing of microsatellite instability in colorectal cancer. World J Gastrointest Oncol (2013) 0.88
Examining the impact of gene variants on histone lysine methylation. Biochim Biophys Acta (2014) 0.88
Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis. Br J Cancer (2015) 0.87
Serrated pathway in colorectal carcinogenesis. World J Gastroenterol (2014) 0.87
Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manag Res (2013) 0.87
Precancerous lesions in colorectal cancer. Gastroenterol Res Pract (2013) 0.86
Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother (2016) 0.86
LINE-1-derived poly(A) microsatellites undergo rapid shortening and create somatic and germline mosaicism in mice. Mol Biol Evol (2012) 0.86
MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations. Sci Rep (2015) 0.86
Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget (2015) 0.85
Drug therapy for hereditary cancers. Hered Cancer Clin Pract (2011) 0.85
Micromanaging the classification of colon cancer: the role of the microRNAome. Clin Cancer Res (2011) 0.85
Genomic instability causes HGF gene activation in colon cancer cells, promoting their resistance to necroptosis. Gastroenterology (2014) 0.84
Patients with genetically heterogeneous synchronous colorectal cancer carry rare damaging germline mutations in immune-related genes. Nat Commun (2016) 0.84
Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. World J Gastroenterol (2012) 0.84
Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients. Int J Mol Sci (2017) 0.83
Current and future molecular diagnostics in colorectal cancer and colorectal adenoma. World J Gastroenterol (2014) 0.82
Establishing a biological profile for interval colorectal cancers. Dig Dis Sci (2014) 0.82
Implications of mismatch repair-deficient status on management of early stage colorectal cancer. J Gastrointest Oncol (2015) 0.81
Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet (2014) 0.81
Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome. Clin Genet (2010) 0.80
Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population: correlation with ancestry markers. Eur J Hum Genet (2013) 0.80
An inducible, isogenic cancer cell line system for targeting the state of mismatch repair deficiency. PLoS One (2013) 0.80
Colon cancer associated genes exhibit signatures of positive selection at functionally significant positions. BMC Evol Biol (2012) 0.80
A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nat Commun (2016) 0.80
Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med (2016) 0.80
Algorithmic methods to infer the evolutionary trajectories in cancer progression. Proc Natl Acad Sci U S A (2016) 0.79
Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma. Clin Epigenetics (2015) 0.79
Gene expression variations in microsatellite stable and unstable colon cancer cells. J Surg Res (2011) 0.79
Next-generation sequencing of colorectal cancers in chinese: identification of a recurrent frame-shift and gain-of-function Indel mutation in the TFDP1 gene. OMICS (2014) 0.79
Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis. Expert Rev Clin Pharmacol (2013) 0.78
Epigenetic regulation of the intestinal epithelium. Cell Mol Life Sci (2015) 0.78
Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype. Epigenetics (2014) 0.78
Molecular markers predictive of chemotherapy response in colorectal cancer. Curr Gastroenterol Rep (2015) 0.78
DNA mismatch repair system: repercussions in cellular homeostasis and relationship with aging. Oxid Med Cell Longev (2012) 0.78
Comparison of the Mismatch Repair System between Primary and Metastatic Colorectal Cancers Using Immunohistochemistry. J Pathol Transl Med (2017) 0.78
Viroimmunotherapy for Colorectal Cancer: Clinical Studies. Biomedicines (2017) 0.77
HGUE-C-1 is an atypical and novel colon carcinoma cell line. BMC Cancer (2015) 0.77
Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence. Br J Cancer (2016) 0.77
GUCY2C ligand replacement to prevent colorectal cancer. Cancer Biol Ther (2016) 0.77
Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer. Cell Biosci (2015) 0.77
The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery. Cell Oncol (Dordr) (2016) 0.77
POLE proofreading mutation, immune response and prognosis in endometrial cancer. Oncoimmunology (2015) 0.76
Downregulation of CRNN gene and genomic instability at 1q21.3 in oral squamous cell carcinoma. Clin Oral Investig (2015) 0.76
Microsatellite instability in sarcoma: fact or fiction? ISRN Oncol (2012) 0.76
Low Level of Microsatellite Instability Correlates with Poor Clinical Prognosis in Stage II Colorectal Cancer Patients. J Oncol (2016) 0.76
Microsatellite instability and loss of heterozygosity detected in middle-aged patients with sporadic colon cancer: A retrospective study. Oncol Lett (2013) 0.76
Distinct molecular features of colorectal cancer in Ghana. Cancer Epidemiol (2013) 0.76
Mismatch Repair Proteins and Microsatellite Instability in Colorectal Carcinoma (MLH1, MSH2, MSH6 and PMS2): Histopathological and Immunohistochemical Study. Open Access Maced J Med Sci (2017) 0.75
Novel Mutations in MLH1 and MSH2 Genes in Mexican Patients with Lynch Syndrome. Gastroenterol Res Pract (2016) 0.75
Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target. Fam Cancer (2016) 0.75
Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract (2013) 0.75
Hypoxia-inducible factor-mediated induction of WISP-2 contributes to attenuated progression of breast cancer. Hypoxia (Auckl) (2014) 0.75
Biomarker correlation network in colorectal carcinoma by tumor anatomic location. BMC Bioinformatics (2017) 0.75
Integrating gene set analysis and nonlinear predictive modeling of disease phenotypes using a Bayesian multitask formulation. BMC Bioinformatics (2016) 0.75
Mutation analysis of 13 driver genes of colorectal cancer-related pathways in Taiwanese patients. World J Gastroenterol (2016) 0.75
Mutanome and expression of immune response genes in microsatellite stable colon cancer. Oncotarget (2016) 0.75
Integrative Omics Analysis Reveals Post-Transcriptionally Enhanced Protective Host Response in Colorectal Cancers with Microsatellite Instability. J Proteome Res (2015) 0.75
Tumor microsatellite instability and clinicopathologic features in Iranian colorectal cancer patients at risk for Lynch syndrome. J Res Med Sci (2015) 0.75
A survey of tandem repeat instabilities and associated gene expression changes in 35 colorectal cancers. BMC Genomics (2015) 0.75
Diverse repetitive element RNA expression defines epigenetic and immunologic features of colon cancer. JCI Insight (2017) 0.75
Highly sensitive, non-invasive detection of colorectal cancer mutations using single molecule, third generation sequencing. Appl Transl Genom (2015) 0.75
DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. J Clin Oncol (2016) 0.75
Genomic Instability in Cancer: Teetering on the Limit of Tolerance. Cancer Res (2017) 0.75
Cancer quasispecies and stem-like adaptive aneuploidy. F1000Res (2013) 0.75
The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy. Oncotarget (2016) 0.75
Familial risk for lung cancer. Oncol Lett (2016) 0.75
Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in Colorectal Cancer. Dis Markers (2016) 0.75
Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. Br J Cancer (2017) 0.75
Molecular classification of esophagogastric junction carcinoma correlated with prognosis. Onco Targets Ther (2017) 0.75
DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. Cancer (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Genome maintenance mechanisms for preventing cancer. Nature (2001) 16.17
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Microsatellite instability in cancer of the proximal colon. Science (1993) 14.51
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (1993) 12.74
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med (2005) 9.39
Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer (2006) 9.15
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med (2000) 8.68
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med (1998) 8.47
Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol (2006) 6.16
Allelotype of colorectal carcinomas. Science (1989) 5.54
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 5.22
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet (2000) 5.04
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst (1998) 4.65
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet (2008) 4.44
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol (2008) 4.13
Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol (2000) 3.98
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol (2007) 3.51
Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res (2002) 3.39
BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res (2003) 3.39
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology (2000) 3.01
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol (2009) 2.94
Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res (2005) 2.92
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology (2009) 2.75
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet (2004) 2.75
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer (2008) 2.68
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene (2003) 2.56
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res (2003) 2.48
BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res (2004) 2.37
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet (2006) 2.33
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res (2004) 2.10
Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol (2003) 1.97
Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res (2003) 1.92
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut (2005) 1.87
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer (2007) 1.79
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer (2009) 1.75
Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer (2009) 1.74
Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev (2009) 1.72
High incidence of microsatellite instability in colorectal cancer from African Americans. Clin Cancer Res (2003) 1.68
Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer (2004) 1.66
Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene (2007) 1.50
Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene (2004) 1.46
The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res (2001) 1.46
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene (2008) 1.46
DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers. Clin Cancer Res (2008) 1.44
Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer (2004) 1.42
Gene expression signatures for colorectal cancer microsatellite status and HNPCC. Br J Cancer (2005) 1.40
Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res (2005) 1.38
Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res (2009) 1.35
Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer (2002) 1.32
Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res (2006) 1.32
PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat (2008) 1.29
Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin (2006) 1.29
Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer (2004) 1.28
Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene (2008) 1.28
A gene expression signature of genetic instability in colon cancer. Cancer Res (2005) 1.23
Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer (2009) 1.23
Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clin Cancer Res (2003) 1.22
A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol (2007) 1.20
Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer (2008) 1.16
Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res (2009) 1.15
High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer (2002) 1.15
Interpretation of microarray data in cancer. Br J Cancer (2007) 1.12
Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res (2008) 1.09
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int J Colorectal Dis (2006) 1.06
New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. Gastroenterology (2006) 1.04
Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. Br J Cancer (2001) 1.03
Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res (2009) 1.03
Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. Clin Cancer Res (2008) 1.00
Adjuvant therapy in stage II colon cancer: current approaches. Oncologist (2005) 0.91
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Statins and cancer prevention. Nat Rev Cancer (2005) 4.12
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res (2006) 3.81
Small changes in expression affect predisposition to tumorigenesis. Nat Genet (2001) 3.37
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology (2009) 2.75
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology (2012) 2.57
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol (2009) 2.38
Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet (2011) 2.35
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw (2010) 2.13
Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst (2005) 2.10
Tests for gene-environment interaction from case-control data: a novel study of type I error, power and designs. Genet Epidemiol (2008) 2.04
Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol (2003) 1.97
Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics (2005) 1.96
BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res (2006) 1.85
Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol (2011) 1.84
Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res (2006) 1.80
A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol (2006) 1.80
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst (2004) 1.76
Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Hum Mutat (2008) 1.76
Testing gene-environment interaction in large-scale case-control association studies: possible choices and comparisons. Am J Epidemiol (2011) 1.69
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res (2011) 1.68
Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology (2004) 1.62
The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev (2006) 1.51
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) (2010) 1.45
Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am J Public Health (2004) 1.42
Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol (2013) 1.36
Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers. Cancer Epidemiol Biomarkers Prev (2011) 1.32
Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. Carcinogenesis (2005) 1.32
Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.31
The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer. Nat Genet (2004) 1.25
Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol (2009) 1.23
Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA (2010) 1.22
Returning individual research results: development of a cancer genetics education and risk communication protocol. J Empir Res Hum Res Ethics (2010) 1.22
Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol (2008) 1.22
FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations. Cancer Epidemiol Biomarkers Prev (2008) 1.22
Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol (2003) 1.20
Sharing genetic test results in Lynch syndrome: communication with close and distant relatives. Clin Gastroenterol Hepatol (2008) 1.20
Genetic anthropology of the colorectal cancer-susceptibility allele APC I1307K: evidence of genetic drift within the Ashkenazim. Am J Hum Genet (2003) 1.16
Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res (2009) 1.15
Common variation in ISL1 confers genetic susceptibility for human congenital heart disease. PLoS One (2010) 1.15
Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol (2013) 1.14
CDKN2A germline mutations in individuals with cutaneous malignant melanoma. J Invest Dermatol (2007) 1.14
A case-control study of levothyroxine and the risk of colorectal cancer. J Natl Cancer Inst (2010) 1.14
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol (2009) 1.11
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat (2012) 1.09
Genetics of colorectal cancer. Oncology (Williston Park) (2006) 1.09
Vulvar melanoma: a report of 20 cases and review of the literature. J Am Acad Dermatol (2004) 1.08
The impact of exposure-biased sampling designs on detection of gene-environment interactions in case-control studies with potential exposure misclassification. Eur J Epidemiol (2014) 1.08
Health behaviors of head and neck cancer patients the first year after diagnosis. Head Neck (2008) 1.06
Cancer risks in BRCA1 carriers: time for the next generation of studies. J Natl Cancer Inst (2002) 1.06
Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int J Cancer (2011) 1.04
Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers. Clin Cancer Res (2004) 1.04
Hereditary prostate cancer as a feature of Lynch syndrome. Fam Cancer (2011) 1.04
Breast cancer characteristics at diagnosis and survival among Arab-American women compared to European- and African-American women. Breast Cancer Res Treat (2008) 1.04
Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer (2011) 1.03
Gene expression differences between colon and rectum tumors. Clin Cancer Res (2011) 1.03
Prevalence and predictors of appropriate colorectal cancer surveillance in Lynch syndrome. Am J Gastroenterol (2010) 1.03
Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes Control (2004) 1.03
Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol (2013) 1.02
MLH1 founder mutations with moderate penetrance in Spanish Lynch syndrome families. Cancer Res (2010) 1.01
EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res (2004) 1.01
Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J Invest Dermatol (2013) 1.00
Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev (2005) 1.00
Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab (2012) 1.00
Human papillomavirus is not associated with colorectal cancer in a large international study. Cancer Causes Control (2010) 0.98
Risk perception and concern among brothers of men with prostate carcinoma. Cancer (2004) 0.97
Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility. BMC Genomics (2008) 0.97
Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. J Natl Cancer Inst (2012) 0.96
Colorectal cancer risk perception on the basis of genetic test results in individuals at risk for Lynch syndrome. J Clin Oncol (2009) 0.96
Genome-wide search for gene-gene interactions in colorectal cancer. PLoS One (2012) 0.96
BRAF and NRAS mutations in spitzoid melanocytic lesions. Mod Pathol (2006) 0.95
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. JAMA Oncol (2015) 0.95
Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol (2012) 0.94
Contemporary outcomes of surgical ventricular septal defect closure. J Thorac Cardiovasc Surg (2013) 0.94
MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. Eur J Hum Genet (2012) 0.94
Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Ann Surg Oncol (2011) 0.94
Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study. JAMA Dermatol (2013) 0.94
Allele-specific expression of APC in adenomatous polyposis families. Gastroenterology (2010) 0.93
A review of statistical methods for testing genetic anticipation: looking for an answer in Lynch syndrome. Genet Epidemiol (2010) 0.93
AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome. Am J Med Genet A (2011) 0.93
Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome. Fam Cancer (2012) 0.93
Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study. JAMA Dermatol (2014) 0.91
CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. Cancer Res (2005) 0.91
Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. Clin Cancer Res (2003) 0.90
Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study. Urology (2004) 0.90
Adenoma-infiltrating lymphocytes (AILs) are a potential marker of hereditary nonpolyposis colorectal cancer. Am J Surg Pathol (2008) 0.89
CDX2-regulated expression of iron transport protein hephaestin in intestinal and colonic epithelium. Gastroenterology (2005) 0.89
History and molecular genetics of Lynch syndrome in family G: a century later. JAMA (2005) 0.88
Higher micronutrient intake is associated with human papillomavirus-positive head and neck cancer: a case-only analysis. Nutr Cancer (2011) 0.88
Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. Thyroid (2009) 0.87